Navigation Links
Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
Date:2/17/2012

ISELIN, N.J., Feb. 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC.

Fourth Quarter Ended December 31, 2011The Company recorded a net loss of $0.4 million, or $0.01 per share, for the fourth quarter 2011 compared to a net loss of $0.2 million, or $0.00 per share, in the fourth quarter 2010.  

During the quarter, the Company paid for some preliminary administrative costs to prepare for the start of a proof-of-concept trial in Gout patients using Levotofisopam in January of 2012. In connection with this trial the Company also incurred consulting fees and costs for the completion of a non-human primate toxicology study. The Company continued to spend for G&A on a conservative basis.

Gross research and development expenses were $198,992 compared to $117,771 in 2010. The Company received a $244,479 cash grant in 2010 under the Federal Qualifying Therapeutic Discovery Project related to the Dextofisopam program and this was shown as a credit to gross R&D in 2010, resulting in a net R&D credit of $126,708. The majority of the increased spending in 2011 was for clinical study fees as the Company paid for preliminary administrative fees for the proof-of-concept Gout trial that commenced in January of 2012 at Duke University.

General and administrative expenses for the fourth quarter of 2011 decreased by $44,409, or 18%, from $251,593 in 2010 to $207,184 in 2011. The primary reductions were a $26,000 reduction in salaries and benefits and an $18,000 reduction in various other areas. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010.  There was also a reduction of various facility related expenses.

At December
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Corporation Reports 2011 Second Quarter Results
2. Pharmos Corporation Reports 2010 Third Quarter Results
3. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
4. Pharmos Corporation Reports 2009 Third Quarter Results
5. Pharmos Issues Business Update on Dextofisopam Trial and Financing
6. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
7. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
8. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
9. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... the Company) (NASDAQ: HOLX ), a leading ... imaging systems and surgical products dedicated to serving the ... (Conceptus) request for an injunction barring future sales of ... and that no royalty will be due to Conceptus ...
... BASIS Science, Inc. ( www.mybasis.com ) the creators of the ... B1 band, will be demoing at the 2012 International CES ... for the first time. The dashboard has been designed as ... health and wellness. "We have designed the Basis ...
Cached Medicine Technology:Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 2Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 3BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2
(Date:7/30/2015)... ... 30, 2015 , ... In a meaningful ritual intended to symbolize a final ... Center have created an addiction graveyard. Sharing this with the public comes at a ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he moved ...
(Date:7/30/2015)... Diego, CA (PRWEB) , ... July 30, 2015 ... ... has been consistently growing into one of the largest, family-owned low cost service ... across residential and commercial applications, as well as growing their company to meet ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility ... effort to provide comfort to patients as well as visiting friends and family during ... phone charging stations. , The stations - powered by ChargeItSpot , a Philadelphia-based ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research Foundation ... Registry Act of 2015’. The bill was introduced in Congress yesterday by Representatives ... McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay ... taxpayer money to fund the state’s large prison system, which has amassed largely enough ... rates of incarceration. In light of President Obama’s recent reduction of non violent drug ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3
... decades, hip replacement surgery has been the only treatment for ... younger patients may replace the traditional replacements.// ,Bobby Castor ... in grade school led to a condition called avascular necrosis. ... the hips drive a golf swing, it hurt Castor’s game. ...
... Laboratory research has found evidence that the venom that ... beneficial effects // on some heart problems, strokes, central ... involved the experimental drug ziconotide, a laboratory-made equivalent of ... Magus cone snail, which lives in shallow tropical saltwater. ...
... IGF-1 will increase substantially risks of breast, colon and ... hormone is a disaster waiting to happen. They say ... -- increases levels of insulin-like growth factor 1 (IGF-1). ... can do. ,Currently, human growth hormone is ...
... the drug gabapentin (Neurontin) taken at 2,400 milligrams ... for people with chronic daily headaches. ,Gabapentin is ... its success in treating other pain-related health issues ... Since gabapentin often reduces migraines by more than ...
... analyzed results from a questionnaire that included more than 4,400 ... the annual British Household Panel Survey, began in 1991. Results ... health, but marriage is better for a woman's . ,Researchers ... work out reported much poorer mental health than men who ...
... drug that strongly activates certain systems in the brain.// ... is often addictive. According to the 2000 National Household ... the United States have tried methamphetamine at least once ... methamphetamine users and 18 healthy people to determine how ...
Cached Medicine News:
Optical Urethrotome 8667 for telescope 4 mm, 0. For slitting urethral strictures under vision...
OES Pro Optical Urethrotome...
... With a 4.9mm insertion tube, ... and increases maneuverability even through strictured ... wide viewing angle of 125 in ... a large viewing area and simplifying ...
New technology in optics, processing and application. Laser-welded mechanics in stainless steel provide high safety in sterilization. Saphire windows distal and proximal, validated even for autoclavi...
Medicine Products: